David Einhorn Bets Citron Research Is Wrong About Chemours Being Designed For Bankruptcy |
| July 27, 2016 | July 2016 Bond Updates |
|
When short seller Andrew Left of Citron Research characterized DuPont spinoff Chemours as a company "purposely designed for bankruptcy" and "a zero" in early June, his comments sent the NYSE-listed company tumbling over 20%. After all, less than a year ago, Left caused an almost crippling investor stampede from Valeant Pharmaceuticals when he published a report accusing the drugmaker of being "Enron part Deux." |
| View more at: http://www.forbes.com/sites/antoinegara/2016/07/26/david-einhorn-andrew-left-chemours-valeant-citron/ |
| Related News |
|